精品国产一区二区桃色

News

Do I need a COVID-19 booster shot?

Six questions answered on how to stay protected
William Petri
By William Petri
July 17, 2021

The increasing prevalence of is raising questions about how well protected those who’ve already had their COVID-19 shots are against evolving forms of the SARS-CoV-2 virus. Here, of the University of Virginia answers some common questions about COVID-19 booster shots.

Booster-445x559.jpg
,
A booster shot may be necessary to maintain COVID-19 immunity.

1. What is a booster shot?

Boosters are an extra dose of a vaccine given to maintain vaccine-induced protection against a disease. They are commonly used to bolster many vaccines because immunity can . For example, the needs a booster every year, and the every 10 years.

Boosters are often identical to the original vaccine. In some cases, however, the booster shot has been modified to enhance protection against new viral variants. The , most notably, requires an annual booster because the flu virus changes so rapidly.

2. Do I need to get a COVID-19 booster?

Not yet. As of early July 2021, none of the U.S. government authorities is recommending a booster. This includes the Centers for Disease Control and Prevention, the Food and Drug Administration and the Advisory Committee on Immunization Practices to the CDC.

3. Why aren’t booster shots recommended yet?

While vaccine-induced immunity may not last forever, it is not clear when a booster will be needed.

Encouragingly, all of the currently authorized COVID-19 vaccines induce a robust immune memory against the coronavirus. The vaccine teaches your immune system’s to produce antibodies when you’re exposed to the virus. Researchers have detected high levels of memory B cells in the lymph nodes of people who received the Pfizer vaccine for after they got the shot.

Studies also suggest that authorized COVID-19 vaccines are continuing to offer protection even against . Among one study’s participants, the Johnson & Johnson vaccine had 14 days and 28 days post shot, respectively, at warding off severe disease from the beta variant. And a preliminary study that has not been peer-reviewed found the Pfizer vaccine to be against the delta variant.

The other source of long-lasting antibody responses against the coronavirus is cells called that reside in bone marrow. These cells continuously produce antibodies and do not require boosting to maintain their activity. Fortunately, plasmablasts have been detected in the bone marrow of for up to 11 months, indicating some degree of long-lasting immune memory.

Booster shots remind your immune system of the pathogen it’s been immunized against.

4. How will I know if I need a booster?

You may need to wait for an outbreak in people who have been vaccinated. Researchers are still figuring out the best way to measure the strength of someone’s vaccine-induced immunity. The COVID-19 vaccines have been so effective that there are not many failures to test.

The best candidate to measure are certain antibodies the vaccine induces the immune system to make. They recognize the that allows the coronavirus to enter and infect cells. Evidence supporting the importance of anti-spike antibodies includes a study showing that the somewhat more effective mRNA vaccines like Pfizer and Moderna generate than the adenovirus vector vaccines like Johnson & Johnson and AstraZeneca. In a that has not yet been peer-reviewed, anti-spike antibody levels were lower in people who caught COVID-19 after they were vaccinated with the Oxford–AstraZeneca vaccine.

Medical workers would love to be able to give patients a blood test that would tell them how well protected they are or aren’t against COVID-19. That would be a clear indication as to whether a booster shot is needed.

But until researchers know for sure how to measure vaccine-induced immunity, the next indication that boosters may be needed are breakthrough infections in older adults who have already been vaccinated. People over the age of 80 make after vaccination, so their immunity may wane sooner than that of the general population. The elderly would also most likely be the that evade the protection current vaccines provide.

5. I’m immunocompromised – should I worry?

Boosters may be necessary for immunocompromised people. In one study, 39 of 40 kidney transplant recipients and a third of dialysis patients . Another study identified 20 patients with on medications that suppress the immune system who also did not have detectable antibodies. Both of these studies were done after patients received the full vaccine dose.

Boosters have been shown to help in these cases. In one study, one-third of who had a suboptimal response to two doses of the Pfizer or Moderna vaccines were able to develop an antibody response with a third dose.

Those who are immunocompromised may wonder if the vaccine they received is successfully generating immunity in their body. A preliminary study that has not yet been peer-reviewed did find that a the vaccines trigger may be helpful in determining whether the vaccine worked. But for now, the antibody tests to assess immunity.

6. Does my booster need to match my first shots?

Likely not. Recent research has shown that mRNA vaccines, like Pfizer and Moderna, can be mixed with adenovirus-based vaccines like AstraZeneca with .

This article is republished from under a Creative Commons license. Read the .

The Conversation

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
William Petri
William Petri

William Petri is a professor of  medicine and microbiology at the University of Virginia who specializes in infectious diseases.

Get the latest from ASBMB Today

Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

RA patient blood reveals joint innerworkings
Journal News

RA patient blood reveals joint innerworkings

July 25, 2025

Researchers in the Netherlands use mass spectrometry to compare the proteome of plasma and synovial fluid in rheumatoid arthritis patients and find a correlation. Read more about this recent paper in Molecular & Cellular Proteomics.

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥 to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Feature

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥 and just getting started.

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader鈥揥illi syndrome.

Using 'nature鈥檚 mistakes' as a window into Lafora disease
Feature

Using 'nature鈥檚 mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer鈥檚 code through functional connections
News

Cracking cancer鈥檚 code through functional connections

July 2, 2025

A machine learning鈥揹erived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.